

# Casper Steenholdt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9047455/publications.pdf>

Version: 2024-02-01

62  
papers

2,220  
citations

304743

22  
h-index

214800

47  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2315  
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. <i>Gut</i> , 2014, 63, 919-927.	12.1	413
2	Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 310-318.	1.5	171
3	Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 51-58.	3.7	135
4	Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 774-781.	1.5	134
5	Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2014, 109, 1055-1064.	0.4	125
6	Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 530-538.	2.0	104
7	Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2209-2217.	1.9	90
8	Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1714-1721.	1.9	90
9	Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 518-527.	1.5	89
10	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1999-2015.	1.9	82
11	Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2762-2770.	2.3	73
12	Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 108-111.	1.3	62
13	Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 238-245.	1.3	56
14	Expression and function of toll-like receptor 8 and Tollip in colonic epithelial cells from patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 195-204.	1.5	46
15	Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 650-659.	3.7	45
16	Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1172-1183.	3.7	43
17	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2016, 55, 257-274.	3.5	42
18	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. <i>BMC Medicine</i> , 2017, 15, 184.	5.5	34

#	ARTICLE	IF	CITATIONS
19	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000208.	2.7	29
20	Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 358-361.	1.3	26
21	Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. <i>AAPS Journal</i> , 2017, 19, 223-233.	4.4	25
22	A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 298-305.	1.3	23
23	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. <i>EClinicalMedicine</i> , 2020, 20, 100271.	7.1	23
24	Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1210-1217.	1.9	21
25	Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNF Therapy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1526-1532.	0.4	20
26	Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-Independent Crohn Disease. <i>Medicine (United States)</i> , 2016, 95, e3417.	1.0	19
27	Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 483-489.	2.2	18
28	Discontinuation of Infliximab Therapy in Patients with Crohn's Disease. , 2022, 1, .		17
29	Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1032-1042.	1.3	16
30	Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. <i>Danish Medical Journal</i> , 2013, 60, B4616.	0.5	16
31	Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 559-568.e5.	4.4	14
32	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 91-101.	3.8	14
33	Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. <i>BMJ Open</i> , 2014, 4, e005887.	1.9	11
34	Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 884-890.	1.5	11
35	Postoperative complications and waiting time for surgical intervention after radiologically guided drainage of intra-abdominal abscess in patients with Crohn's disease. <i>BJS Open</i> , 2021, 5, .	1.7	11
36	Transient and Persistent Antibodies Against TNF-Inhibitors in IBD. <i>American Journal of Gastroenterology</i> , 2015, 110, 1623-1624.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1583-1591.	2.3	8
38	Authors'™ response: Importance of defining loss of response before therapeutic drug monitoring. <i>Gut</i> , 2015, 64, 1340-1341.	12.1	6
39	Methotrexate for inflammatory bowel disease: time for reconsideration. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 407-409.	3.0	6
40	Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. <i>Stem Cells</i> , 2022, 40, 447-457.	3.2	6
41	Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 404-405.	3.7	5
42	Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies. <i>Danish Medical Journal</i> , 2016, 63, .	0.5	5
43	Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 597-598.	4.4	4
44	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 235-242.	2.0	4
45	A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients'™ and physicians'™ preferences and adherence. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 274-281.	1.5	4
46	Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-7.	1.5	4
47	Outcome of continued infliximab therapy in Crohn's™ disease patients with response but without remission after one year of infliximab " a retrospective cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 930-937.	1.5	3
48	Monitoring immunogenicity of protein-based TNF antagonists. <i>Frontline Gastroenterology</i> , 2016, 7, 152-154.	1.8	2
49	Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 759-760.	3.7	2
50	Severe ulcerative oesophagitis caused by primary Epstein-Barr virus infection in an immunocompetent individual. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000586.	2.7	2
51	Tu1006 " Development of an Evidence-Based Strategy Incorporating Patient Reported Outcomes and Physicians'™ Preferences to Monitor Biological Therapies in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2019, 156, S-943-S-944.	1.3	1
52	Drug Levels Associated with Optimal Discrimination Between Remission and Non-Remission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, .	2.0	1
53	Herpes Zoster Meningoencephalitis: A Novel, Rare, Potentially Fatal Side Effect to Tofacitinib. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, 195-196.	0.4	1
54	P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S409-S409.	1.3	0

#	ARTICLE	IF	CITATIONS
55	P377 Clinical strategies based on patient-reported outcomes and physicians' preferences to monitor biological therapy in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S294-S294.	1.3	0
56	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2456.	4.4	0
57	P381 Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S394-S395.	1.3	0
58	P599 Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S545-S546.	1.3	0
59	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
60	P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i441-i441.	1.3	0
61	Localised colonic AL amyloidosis: a rare manifestation of a rare disease. <i>Frontline Gastroenterology</i> , 2023, 14, 171-172.	1.8	0
62	Colonic actinomycosis mimicking malignant stenosing tumors. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0